Eswatini vs Republic of Moldova: Average cost of multi drug-resistant tuberculosis treatment
Eswatini
840 constant 2022 US$
in 2024
Republic of Moldova
824 constant 2022 US$
in 2024
Eswatini rank
59th
Republic of Moldova rank
60th
Average cost of multi drug-resistant tuberculosis treatment over time
- Eswatini
- Republic of Moldova
How they compare
Eswatini currently reports 840 constant 2022 US$ against 824 constant 2022 US$ in Republic of Moldova, a difference of 16 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Eswatini ahead.
Eswatini ranks 59th and Republic of Moldova ranks 60th of 92 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Republic of Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,118 constant 2022 US$ | 2,572 constant 2022 US$ | 3,546 constant 2022 US$ | Eswatini |
| 2020s | 2,824 constant 2022 US$ | 1,372 constant 2022 US$ | 1,452 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eswatini or Republic of Moldova?
- Eswatini, at 840 constant 2022 US$ against 824 constant 2022 US$ in Republic of Moldova as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eswatini and Republic of Moldova?
- 16 constant 2022 US$, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Republic of Moldova?
- 8 years are reported by both, from 2017 to 2024.
- How do Eswatini and Republic of Moldova rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eswatini ranks 59th and Republic of Moldova ranks 60th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.